Skip Nav Destination
Issues
15 October 2012
-
Cover Image
Cover Image
This figure shows the interface between tumor and normal tissues that define the margin of a cancer. Obtaining disease-free margins remains the most challenging aspect of successful surgical resection of solid cancers. Near-infrared imaging can be used to identify the margins of tumors during surgery in order to improve disease clearance and reduce local recurrences. For details, see the article by Madajewski and colleagues on page 5741 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Molecular Pathways
CCR Focus
Human Cancer Biology
A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma
Robert Fouret; Julien Laffaire; Paul Hofman; Michèle Beau-Faller; Julien Mazieres; Pierre Validire; Philippe Girard; Sophie Camilleri-Bröet; Fabien Vaylet; François Leroy-Ladurie; Jean-Charles Soria; Pierre Fouret
14-3-3ζ, a Novel Androgen-Responsive Gene, Is Upregulated in Prostate Cancer and Promotes Prostate Cancer Cell Proliferation and Survival
Taro Murata; Ken-ichi Takayama; Tomohiko Urano; Tetsuya Fujimura; Daisaku Ashikari; Daisuke Obinata; Kuniko Horie-Inoue; Satoru Takahashi; Yasuyoshi Ouchi; Yukio Homma; Satoshi Inoue
Cancer Therapy: Preclinical
Carfilzomib and ONX 0912 Inhibit Cell Survival and Tumor Growth of Head and Neck Cancer and Their Activities Are Enhanced by Suppression of Mcl-1 or Autophagy
Yan Zang; Sufi M. Thomas; Elena T. Chan; Christopher J. Kirk; Maria L. Freilino; Hannah M. DeLancey; Jennifer R. Grandis; Changyou Li; Daniel E. Johnson
CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs
Mike I. Walton; Paul D. Eve; Angela Hayes; Melanie R. Valenti; Alexis K. De Haven Brandon; Gary Box; Albert Hallsworth; Elizabeth L. Smith; Kathy J. Boxall; Michael Lainchbury; Thomas P. Matthews; Yann Jamin; Simon P. Robinson; G. Wynne Aherne; John C. Reader; Louis Chesler; Florence I. Raynaud; Suzanne A. Eccles; Ian Collins; Michelle D. Garrett
Imaging, Diagnosis, Prognosis
Gene Expression Signature–Based Prognostic Risk Score in Patients with Primary Central Nervous System Lymphoma
Atsushi Kawaguchi; Yasuo Iwadate; Yoshihiro Komohara; Masakazu Sano; Koji Kajiwara; Naoki Yajima; Naoto Tsuchiya; Jumpei Homma; Hiroshi Aoki; Tsutomu Kobayashi; Yuko Sakai; Hiroaki Hondoh; Yukihiko Fujii; Tatsuyuki Kakuma; Ryuya Yamanaka
A Prospective PCR-Based Screening for the EML4-ALK Oncogene in Non–Small Cell Lung Cancer
Manabu Soda; Kazutoshi Isobe; Akira Inoue; Makoto Maemondo; Satoshi Oizumi; Yuka Fujita; Akihiko Gemma; Yoshihiro Yamashita; Toshihide Ueno; Kengo Takeuchi; Young Lim Choi; Hitoshi Miyazawa; Tomoaki Tanaka; Koichi Hagiwara; Hiroyuki Mano; for the North-East Japan Study Group and the ALK Lung Cancer Study Group
Cancer Therapy: Clinical
Clinicopathologic Features and Long-term Outcomes of NUT Midline Carcinoma
Daniel E. Bauer; Chelsey M. Mitchell; Kelly M. Strait; Christopher S. Lathan; Edward B. Stelow; Sonja C. Lüer; Somala Muhammed; Andrew G. Evans; Lynette M. Sholl; Juan Rosai; Eugenia Giraldi; Richard P. Oakley; Carlos Rodriguez-Galindo; Wendy B. London; Stephen E. Sallan; James E. Bradner; Christopher A. French
A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients
Karel Eechoute; Martin N. Fransson; An K. Reyners; Floris A. de Jong; Alex Sparreboom; Winette T.A. van der Graaf; Lena E. Friberg; Gaia Schiavon; Erik A.C. Wiemer; Jaap Verweij; Walter J. Loos; Ron H.J. Mathijssen; Ugo De Giorgi
Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity
John Moroney; Siqing Fu; Stacy Moulder; Gerald Falchook; Thorunn Helgason; Charles Levenback; David Hong; Aung Naing; Jennifer Wheler; Razelle Kurzrock
Predictive Biomarkers and Personalized Medicine
Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome
Zhigang C. Wang; Nicolai Juul Birkbak; Aedín C. Culhane; Ronny Drapkin; Aquila Fatima; Ruiyang Tian; Matthew Schwede; Kathryn Alsop; Kathryn E. Daniels; Huiying Piao; Joyce Liu; Dariush Etemadmoghadam; Alexander Miron; Helga B. Salvesen; Gillian Mitchell; Anna DeFazio; John Quackenbush; Ross S. Berkowitz; J. Dirk Iglehart; David D.L. Bowtell; for the Australian Ovarian Cancer Study Group; Ursula A. Matulonis
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds